Eli Lilly’s Stock Races Toward Record Territory as Obesity and Depression Data Converge

Lilly shares surge 20% as Retatrutide delivers 30% weight loss, Foundayo beats Novo Nordisk in diabetes. FDA submission for oral GLP-1 pill due by June.

Eli Lilly’s shares have surged nearly 20% over the past month as investors digest a barrage of clinical wins spanning obesity, diabetes, and a nascent psychiatric pipeline. The stock now trades at €1,008, within striking distance of its all-time high, with the next major catalyst — an FDA submission for the oral GLP-1 pill Foundayo — expected before the end of June. On a separate quote, the shares were recently cited at €987, some 5.5% below the 52-week peak hit on June 8, underscoring the rapid pace of appreciation.

The heavyweight among the latest readouts is Retatrutide, a triple-receptor agonist. In the TRIUMPH-1 study, patients on the 12 mg dose shed an average of 28.3% of body weight over 80 weeks, equivalent to roughly 32 kg. Notably, 45.3% of participants achieved at least 30% weight loss — a threshold previously associated almost exclusively with bariatric surgery. An extension study stretching to 104 weeks pushed the average loss to 30.3% in patients with a BMI of 35 or higher. Beyond weight reduction, Retatrutide improved knee osteoarthritis pain by up to 73% and cut sleep apnea events by more than 60%. Full phase-3 results from TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (cardiovascular disease) are due later this year, with a regulatory submission planned for 2026.

Lilly also unveiled data for Foundayo (orforglipron), an oral GLP-1 pill that does not require fasting — a key advantage over Novo Nordisk’s oral semaglutide. In the head-to-head ACHIEVE-3 trial, Foundayo lowered HbA1c by 2.2 percentage points versus 1.4 points for oral semaglutide. More strikingly, 37.1% of Foundayo patients achieved a normal HbA1c below 5.7%, compared with just 12.5% on the competitor’s drug. BMO Capital Markets said the data further cement Foundayo’s position in the type 2 diabetes market. Lilly plans to file for FDA approval in diabetes before the end of the second quarter using a priority review voucher, and regulatory applications are already underway in more than 40 countries.

Less known is Lilly’s push into psychiatry with Brenipatide, a once-monthly injectable that activates the same GLP-1 and GIP receptors as tirzepatide but is being tested as an add-on to existing antidepressants in major depressive disorder. The phase-3 RENEW-MDD 1 study aims to delay relapse rather than replace current medications. Two phase-2 trials are also evaluating Brenipatide in bipolar disorder and schizophrenia, but results are likely years away. Jefferies responded by raising its price target to $1,350 and reiterating a buy rating, while Bernstein also maintained a buy recommendation.

Analysts see Lilly’s next-generation portfolio leaving rivals trailing. RBC’s Trung Huynh noted that data from Novo Nordisk, Roche, and other competitors are comparable to existing therapies, while Lilly’s pipeline is in a different league. Pfizer’s oral GLP-1 candidate Danuglipron continues to struggle with tolerability, remaining well behind Foundayo. The financial strength underpinning these ambitions is clear: first-quarter 2026 revenue surged 56% to $19.8 billion, and the company raised its full-year guidance to a range of $82–$85 billion.

Technically, the stock sits about 18% above its 50-day moving average, with the relative strength index at 70.8 — a level that typically signals overbought conditions. Still, the upcoming Foundayo submission and continued Retatrutide data are expected to provide further catalysts. With a pipeline that now stretches from metabolic diseases to central nervous system disorders, Lilly is building a platform that could eventually span three major therapeutic fields. For now, investors are fixated on the near-term regulatory deadline and a steady stream of obesity data that continues to redefine expectations.